MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

MiMedx Group Inc

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MiMedx Group (MDXG – Research Report), TransMedics Group (TMDX – ...

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS)

MiMedx Group ( ($MDXG) ) just unveiled an update. MiMedx Group reported a record revenue of $114 million for the third quarter of 2025, marking a 3...

Market Cap	$1.04B	P/E Ratio	18.27
52W High	$10.14	52W Low	$5.79
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	57.9%	52W Position	22.3%
Overall Score	57	Value Score	65
Quality Score	--	Technical Score	50

EPS Current Est	$0.37	EPS Next Est	$0.27
EPS Growth Est	-27.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDXG	$6.76	+3.21%	836.84K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDXG	$6.76	+3.2%	836.84K
3
4
5
6

MDXG

MDXG

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get MiMedx Group Inc Data in Excel

Get MiMedx Group Inc Data in Excel